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Objectives: To investigate whether tumour necrosis factor a
(TNFa) is expressed in subacute cutaneous lupus erythema-
tosus (SCLE) skin lesions.
Methods: The in situ expression of TNFa in refractory
lesional and non-lesional skin biopsy specimens from
patients with SCLE was analysed using an immunohisto-
chemical approach. At the time of biopsy these patients were
receiving treatment with systemic medications such as
antimalarial agents, immunosuppressive drugs, and thalido-
mide. Expression of TNFa was also evaluated in cutaneous
lesions of patients with other inflammatory and neoplastic
skin diseases as controls.
Results: The data showed that refractory lesional skin tissue
from patients with SCLE displays a strongly positive distribu-
tion of TNFa, particularly within the epidermis. No prominent
staining was seen in non-lesional skin from the same group of
patients or in cutaneous lesions from the control group.
Conclusions: These findings suggest that TNFa is localised
and produced by epidermal cells within SCLE skin lesions
and support its potential role in the pathogenesis of SCLE.
The tissue localisation of TNFa may represent a potential
therapeutic target providing a new perspective in the
treatment of refractory skin lesions in patients with SCLE.
M
any cytokines, including tumour necrosis factor a
(TNFa), seem to have a significant role in the
inflammatory process, as well as in the regulation of
the autoimmune response in systemic lupus erythematosus
(SLE).
High serum levels of this cytokine and receptors (sTNFRI
and sTNFRII) have been detected in patients with SLE in
correlation with disease activity,1 2 even during pregnancy.3
It is worth noting that the increased TNFa found in SLE
sera is bioactive,4 supporting the hypothesis that TNFa
contributes to the pathogenesis of some lupus manifesta-
tions.4 In addition, TNFa has been specifically immunoloca-
lised in kidney sections from patients with SLE and
glomerulonephritis5 in correlation with histological activity.
TNFa is produced by a variety of cells, including those of
the epidermis; in particular, keratinocytes are a potent source
of cytokines.6
Subacute cutaneous lupus erythematosus (SCLE) is one of
the LE-specific skin lesions consisting of non-scarring
papulosquamous or annular skin lesions that occur in
characteristic photodistribution.7 About 75% of SCLE can be
managed with conventional topical and systemic treatment;
in the remaining 25% of cases skin lesions can be particularly
severe and refractory to conventional treatment.
Our study aimed at investigating the in situ expression of
TNFa in cutaneous lesions in patients with SCLE.
PATIENTS AND METHODS
Patients and skin biopsies
Upon informed consent, excisional biopsy specimens of
lesional and non-lesional sun protected skin were obtained
from four patients with SLE (American Rheumatism
Association criteria) with specific and diagnostic cutaneous
manifestations of SCLE according to Gilliam and
Sontheimer’s classification.7
Detection of autoantibodies
Antinuclear antibodies and anti-double stranded DNA anti-
bodies were detected by indirect immunofluorescence tech-
nique, on HEp-2 cells and Crithidia luciliae, respectively.
Antibodies against extractable nuclear antigens were tested
by immunoblotting technique on cytoplasmic and nuclear
cell extracts from Raji cultured cells.
Antibodies directed against SSA/Ro and SSB/La antigens
were also tested by enzyme linked immunosorbent assay
(ELISA) (INOVA Diagnostics, Inc), following the manufac-
turer’s instructions.
TNFa serum levels
TNFa was measured in the serum of patients with SCLE by
chemiluminescence immunoassay using an automated ana-
lyser (Immulite, DPC) and anti-TNFa monoclonal antibody
(DPC, Biermann GmbH).
Direct immunofluorescence
Cryosections of 4 mm thickness from lesional and non-
lesional skin biopsy specimens were mounted on Polysine
glass slides and air dried for 30 minutes. The sections were
then stained for 30 minutes in a moist chamber at room
temperature, using fluorescein isothiocyanate labelled, rabbit
antibodies against human IgG, IgA, IgM, C3, C1q, and C4
(Dako, Glostrup, Denmark). Conjugate dilutions were made
in 0.01 M phosphate buffered saline (PBS), pH 7.3, supple-
mented with 1% bovine serum albumin. After washing in
PBS for 30 minutes, the sections were coverslipped under
fresh PBS/glycerol (50% vol/vol).
Immunohistochemistry
Detection of TNFa was performed on frozen sections from
four samples of active lesions of SCLE, four of normal human
skin obtained from sun protected areas of the same patients,
Abbreviations: APAAP, alkaline phosphatase anti-alkaline
phosphatase; mAbs, monoclonal antibodies; PBS, phosphate buffered
saline; SCLE, subacute cutaneous lupus erythematosus; SLE, systemic
lupus erythematosus; TNFa, tumour necrosis factor a
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three samples of mycosis fungoides, three of cutaneous T cell
pseudolymphoma, and two of parapsoriasis.
Samples were stained with the following monoclonal
antibodies (mAbs): anti-TNFa (clone 68B6A3L1; BioSource
Europe, Nivelles, Belgium),8 anti-CD3 (clone UCHT1; Dako),
anti-CD1a (clone NA1/34; Dako), and anti-CD19 (clone
HD37; Dako).
Air dried, acetone fixed, frozen sections were incubated
overnight with the mAbs and, after washing, processed with
a standard alkaline phosphatase anti-alkaline phosphatase
(APAAP) technique. Rabbit antimouse immunoglobulin
(Dako) was applied for 30 minutes and, after washing, the
sections were incubated with APAAP complex (Dako) for
30 minutes. Naphthol-AS-MX phosphate together with fast
red TR salt were used for the development of alkaline
phosphatase. The endogenous alkaline phosphatase was
blocked by adding levamisole to the substrate. Sections were
counterstained for 5 minutes with Mayer’s haematoxylin.
Negative controls were performed by omitting the
primary mAb on samples or consisted of replacement of the
primary antibody with another irrelevant mAb of identical
isotype.
Table 1 Prominent features at the time of biopsy in our patients affected with SCLE
Characteristics Patient 1 Patient 2 Patient 3 Patient 4
Sex/age (years) F/28 F/37 F/33 F/49
Disease duration (years) 6 14 14 11
Skin lesion duration (months) 60 170 12 134
Type of skin lesion Papulosquamous Papulosquamous Annular/polycyclic Annular/polycyclic
Biopsy site:
Lesional skin Back Shoulder Back Chest
Non-lesional skin Gluteus Gluteus Gluteus Gluteus
TNFa staining Moderate Moderate Moderate Strong
TNFa serum levels (ng/l)* 18.6 13.0 7.3 9.9
ECLAM 6 4 1 2
Clinical manifestations:
Arthritis + – – –
Pericarditis – – – –
Pleuritis – – – –
Renal disease – – – –
Haematological disorders + + – –
Neurological disorders – + – –
Autoantibodies:
ANA + + + +
Anti-dsDNA – + – –
Anti-La/SSB – – + –
Anti-Ro/SSA 60 kDa – – + +
Anti-Ro/SSA 52 kDa – – + –
Anti-ribosomal P proteins + + – –
Anti-Sm – + – –
Prednisone (mg/day) 25 10 5 5
Other treatment MMF MMF, HCQ HCQ, AZA HCQ
Thalidomide (mg/day) – – – 25
*Reference level 8.1 ng/l.
F, female; ECLAM, European Consensus Lupus Activity Measure; ANA, antinuclear antibodies; MMF, mycophenolate mofetil; HCQ, hydroxychloroquine; AZA,
azathioprine.
Figure 1 Representative image of strong immunohistochemical staining of TNFa in a case of SCLE (patient No 4). TNFa is clearly expressed in the
epidermal compartment of lesional skin (A and B), whereas it is absent in the epidermis of non-sun-exposed skin from the same patient (C). A high
power magnification of the positive epidermal areas is shown (B).
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RESULTS
Table 1 summarises the demographic, clinical, and immuno-
logical data of the patients at the time of the biopsy.
All patients were treated initially with topical corticoster-
oids. Because topical treatment did not provide adequate
improvement of the skin lesions, patients were treated with
conventional systemic treatment, and three of the four also
with thalidomide. At the time of biopsy only one patient was
still receiving treatment with thalidomide, because the other
two patients had stoped treatment owing to the occurrence of
peripheral neuropathy. Moreover, at the time of biopsy one
patient was not taking antimalarial drugs because they had
been withdrawn owing to side effects (itch).
Two independent observers, blindly identified moderate to
strong staining of TNFa in the lesional epidermis of the four
samples of SCLE (table 1, figs 1 and 2). Positive staining was
observed on keratinocytes of all layers of the epidermal
compartment. In particular, no correlation between TNFa
tissue localisation and duration of skin lesions or systemic
treatment was seen in any of the patients (table 1). Samples
of both the sun protected normal skin from patients with
SCLE and the pathological skin conditions investigated were
negative for TNFa immunostaining.
TNFa serum levels were higher than the reference level in
patients Nos 1 and 2, and borderline in patient No 4 (table 1)
and the TNFa level seemed to parallel the ECLAM score. No
relationship between the TNFa serum levels and their
expression in lesional skin tissue was found.
A mild (cases 1 and 2) to moderate (cases 3 and 4) dermal
lymphocyte infiltrate was seen in lesional skin of all cases of
SCLE. The predominant cells at the dermal-epidermal inter-
face were identified as CD3+ T lymphocytes, whereas CD19+
B cells were generally absent. CD1a expression was generally
reduced in the epidermal compartment of affected skin of
SCLE, in comparison with sun protected normal skin from
the same patient.
Direct immunofluorescence of lesional skin showed
deposition along the dermal-epidermal junction of IgG,
IgM, C3, C1q in cases 1 and 2, IgM in case 3, IgG, IgM,
and C3 in case 4.
DISCUSSION
It has been demonstrated that there is a strong association of
the polymorphism of –308A promoter of TNFa linked to HLA-
DR3 with SCLE.9 Recently, similar findings have been
reported also in children affected with cutaneous neonatal
lupus, a type of skin lesion which resembles SCLE.10 In
addition, in the same study it was shown that TNFa is
expressed within the epidermis of lesional skin biopsy
specimens from affected children.10 These findings support
the hypothesis of a pathogenetic role of this proinflammatory
cytokine in the pathogenesis of cutaneous neonatal lupus.
In our study, we observed that lesional skin of patients
with SCLE was characterised by an increased expression of
TNFa in comparison with normal skin obtained from the
same patient and with a small group of inflammatory and
neoplastic skin conditions. TNFa immunostaining was
mainly localised in the epidermal compartment, suggesting
that keratinocytes are the major source of this cytokine
during the cutaneous inflammatory process.
A moderate dermal lymphocyte infiltrate was generally
detected in lesional skin biopsies investigated, and the
characterisation of cell infiltrates showed the presence of
CD3+ cells, whereas CD19+ B cells were almost absent. No
correlation was found between TNFa immunostaining or
CD3+ dermal infiltrates and skin lesions or the duration of
systemic treatment.
In addition, CD1a+ cells were reduced in lesional skin
biopsy specimens compared with non-lesional skin from the
same patient. CD1a is expressed in differentiated antigen
presenting cells and monocytes and is used as a marker for
the presence of Langerhans’ cells in the skin.11 Skin antigen
presenting cells (Langerhans’ cells) constitute a subset of
dendritic cells which appear to have an important role in the
initiating events that lead to the T cell mediated immune
responses in skin. Our findings indicate that these cells may
not have a pivotal role in the immunopathological mechan-
ism involved in the development of cutaneous lesions in
SCLE.
We found that TNFa serum levels were associated with
disease activity, but we did not find a relation between the
Figure 2 Representative image of moderate staining of TNFa in a case of SCLE (patient No 1). In the lesional skin, TNFa is expressed within the
epidermis (A) and positive dermal lymphocyte infiltrate can be identified as well (A). The sun protected normal skin from the same patient is negative
(B). Representative image of negative TNFa staining in a control case of parapsoriasis (C).
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level of TNFa in the sera and the intensity of the
immunostaining on skin tissue. These findings support the
hypothesis that TNFa is locally produced by keratinocytes
and could have not leaked from the patient’s circulation into
inflammatory lesions, binding to TNF receptors locally.
There is strong evidence that thalidomide, a TNFa blocking
agent, can be very effective in the treatment of some
refractory SCLE. However, the relevant side effects of this
drug have to be carefully considered. In fact, thalidomide is
highly teratogenic and can induce irreversible peripheral
neuropathy.12
Recently, an open label study on patients treated with a
chimeric anti-TNFa antibody in addition to conventional
treatment, showed a clinical improvement in the inflamma-
tory manifestations of the disease, although the development
of autoantibodies in those patients has been reported.13 The
possibility of inducing cutaneous LE during anti-TNFa
treatment has to be considered as a possible side effect.14
The results of our study indicating the presence of TNFa in
the epidermal compartment of active lesions of SCLE are
consistent with the hypothesis of localised and site-specific
contribution of TNFa to the pathogenesis of the skin disease.
Successful treatment with TNFa blockers in a patient with
SCLE15 and our findings suggest that anti-TNFa might be
useful in the treatment of selected cases of refractory SCLE.
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